ARRIVENT BIOPHARMA, INC. Form D Notices of Exempt Offering of Securities
Notices filed with the SEC for securities sold without registration under Regulation D or Section 4(a)(5), newest first. Values are as filed.
- 2022-12-29: Federal exemption Rule 506(b); Types of securities offered Equity; Date of first sale 2022-12-16; Total offering amount $145,000,000.
- 2022-02-14: Federal exemption Rule 506(b); Types of securities offered Equity; Date of first sale 2021-06-09; Total offering amount $150,000,000.
- 2021-06-23: Federal exemption Rule 506(b); Types of securities offered Equity; Date of first sale 2021-06-09; Total offering amount $90,000,000.
| Filed | Federal exemption | Types of securities offered | Date of first sale | Total offering amount | Total amount sold | Total remaining to be sold | Investors who have already invested |
|---|---|---|---|---|---|---|---|
| 2022-12-29 | Rule 506(b) | Equity | 2022-12-16 | $145,000,000 | $109,999,989 | $35,000,011 | 17 |
| 2022-02-14 D/A | Rule 506(b) | Equity | 2021-06-09 | $150,000,000 | $150,000,000 | $0 | 10 |
| 2021-06-23 | Rule 506(b) | Equity | 2021-06-09 | $90,000,000 | $81,000,000 | $9,000,000 | 9 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |